With launches on the way in the US and EU, MC2 turns attention to the rest of its pipeline

Over the next 12 months, MC2 Therapeutics will start three new clinical studies with the follow-up drugs to Wynzora, which will soon be launched in the US and Europe.

Photo: MC2 Therapeutics / PR

The launch of psoriasis drug Wyzora alongside Epi Health marks the beginning of a new era for MC2 Therapeutics.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs